40926-66-7

Usage

Uses

Used in Pharmaceutical Industry:
Oxazolo[4,5-b]pyridin-2-amine is used as a key component in drug design and development for its potential therapeutic effects against various diseases and conditions. Its unique structure allows for the creation of new pharmaceutical agents that can target specific biological pathways.
Used in Antimicrobial Applications:
Oxazolo[4,5-b]pyridin-2-amine is utilized as an antimicrobial agent, demonstrating potential effectiveness against a range of microorganisms. Its ability to disrupt microbial processes makes it a valuable asset in the development of new antibiotics and antimicrobial treatments.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Oxazolo[4,5-b]pyridin-2-amine serves as an interesting target for further research and development. Its unique structure and properties open up possibilities for the creation of novel compounds with specific therapeutic applications, contributing to the advancement of medical treatments.

Upstream product

• 16867-03-1 2-amino-3-hydroxypyridine 
• 506-68-3 bromocyane 
• 104619-51-4 di(1H-imidazol-1-yl)methanimine 

Downstream Products

• 79014-97-4 3-(Oxazolo[4,5-b]pyridin-2-ylamino)-3-phenyl-propionic acid ethyl ester 
• 1380645-94-2 3-(4-Fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-N-oxazolo[4,5-b]pyridin-2-yl-propionamide 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of substituted 2-acylamide-1,3-benzo[d]zole analogues as agents against MDR- and XDR-MTB

N-(5-Chlorobenzo[d]oxazol-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamideox-amide has been identified as a potent inhibitor of Mtb H37Rv, with a minimum inhibitory concentration (MIC) of 0.42 μM. In this study, a series of substituted 2-acylamide-1,3-zole analogues were designed and synthesized, and their anti-Mtb activities were analyzed. In total, 17 compounds were found to be potent anti-Mtb agents, especially against the MDR- and XDR-MTB strains, with MIC values 10 μM. These analogues can inhibit both drug-sensitive and drug-resistant Mtb. Four representative compounds were selected for further profiling, and the results indicate that compound 18 is acceptably safe and has favorable pharmacokinetic (PK) properties. In addition, this compound displays potent activity against Gram-positive bacteria, with MIC values in the range of 1.48–11.86 μM. The data obtained herein suggest that promising anti-Mtb candidates may be developed via structural modification, and that further research is needed to explore other compounds.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

Amido Compounds

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.